Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
3.690
+0.050 (1.37%)
At close: Jun 5, 2025, 4:00 PM
3.690
0.00 (0.00%)
After-hours: Jun 5, 2025, 4:32 PM EDT
Akebia Therapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Akebia Therapeutics stock ranges from a low of $6.00 to a high of $8.00. The average analyst price target of $6.90 forecasts a 86.99% increase in the stock price over the next year.
Price Target: $6.90 (+86.99%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Akebia Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 3 |
| Buy | 0 | 0 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 2 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +116.80% | Jun 4, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $7 | Buy | Initiates | $7 | +89.70% | Apr 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +103.25% | Apr 4, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +62.60% | Apr 1, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +62.60% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
197.53M
from 160.18M
Increased by 23.32%
Revenue Next Year
296.09M
from 197.53M
Increased by 49.90%
EPS This Year
-0.17
from -0.33
EPS Next Year
n/a
from -0.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 216.5M | 415.3M | 404.9M | ||
| Avg | 197.5M | 296.1M | 330.8M | ||
| Low | 174.8M | 205.2M | 262.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 35.1% | 110.3% | 36.7% | ||
| Avg | 23.3% | 49.9% | 11.7% | ||
| Low | 9.1% | 3.9% | -11.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.06 | 0.44 | 0.37 | |
| Avg | -0.17 | - | 0.18 | |
| Low | -0.35 | -0.31 | -0.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.